Inozyme Pharma, INC

BioMarin Pharmaceutical Inc. has successfully completed its acquisition of Inozyme Pharma, Inc. for $4.00 per share in cash, resulting in Inozyme becoming a wholly-owned subsidiary and its shares being delisted from the Nasdaq Global Select Market.

Inozyme Pharma, Inc. announced the postponement of its 2025 Annual Meeting of Stockholders due to its pending acquisition by BioMarin Pharmaceutical Inc.

Inozyme Pharma, Inc. has approved significant cash transaction bonuses for its Chief Financial Officer and Chief Operating Officer, contingent on their continued employment through the closing of the previously announced merger with BioMarin Pharmaceutical, Inc.

BioMarin is set to acquire Inozyme Pharma in a $270 million deal, adding INZ-701, a Phase 3 enzyme replacement therapy for ENPP1 Deficiency, to its portfolio.

Inozyme Pharma announced positive interim data from its ENERGY 3 trial highlighting INZ-701's potential in treating ENPP1 Deficiency, along with the appointment of Petra Duda as Chief Medical Officer.

Inozyme Pharma is focusing on its ENPP1 Deficiency program, leading to a workforce reduction of approximately 25% and extending its cash runway into the first quarter of 2026.

Inozyme Pharma is focusing on its ENPP1 Deficiency program after reporting a net loss of $28.0 million for the first quarter of 2025.

Inozyme Pharma continues to advance its clinical trials for INZ-701, reporting positive interim data and progress across multiple programs.

Inozyme Pharma continues to advance its clinical trials for INZ-701, reporting positive data and anticipating key milestones in the development of treatments for rare diseases.

Inozyme Pharma's first quarter 2024 results highlight progress in clinical trials for INZ-701 and financial updates.

Inozyme Pharma's 2024 10-K filing highlights a strategic shift towards prioritizing its ENPP1 Deficiency program while postponing trials for ABCC6 Deficiency and calciphylaxis.

Inozyme Pharma's 2023 annual report highlights progress in clinical trials for INZ-701 and provides a financial update.

Sanjay Subramanian, SVP, CFO & Head of BD of Inozyme Pharma, Inc., disposed of all his common stock, restricted stock units, and stock options as part of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share.

Inozyme Pharma's Chief Operating Officer, Matthew Winton, disposed of all his common stock, restricted stock units, and stock options as a result of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share.

Inozyme Pharma Director Axel Bolte disposed of common stock and stock options as part of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share, effective July 1, 2025.

Inozyme Pharma Director Lynne Sullivan reported the disposition of stock options as Inozyme Pharma, Inc. completed its merger with BioMarin Pharmaceutical Inc. at $4.00 per share, resulting in cash payouts for eligible options.

Inozyme Pharma, Inc. has been acquired by BioMarin Pharmaceutical Inc. for $4.00 per share in cash, with the merger effective July 1, 2025, resulting in the cancellation and cash conversion of outstanding equity awards.

Inozyme Pharma Director Robert Hopfner disposed of over 4.49 million shares of common stock at $4.00 per share following the completion of the merger with BioMarin Pharmaceutical Inc.

Inozyme Pharma, Inc. announced the postponement of its 2025 Annual Meeting of Stockholders due to its pending acquisition by BioMarin Pharmaceutical Inc.

Inozyme Pharma will hold its annual stockholders meeting virtually on June 25, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Inozyme Pharma announces its 2025 annual meeting of stockholders to be held virtually on June 25, 2025, featuring the election of directors and ratification of the company's accounting firm.

Inozyme Pharma will hold its annual stockholders meeting on June 18, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

Inozyme Pharma will hold its 2024 annual meeting of stockholders virtually on June 18, 2024, to vote on the election of directors and ratification of the company's independent auditor.

Pivotal bioVenture Partners and its affiliates have ceased to be beneficial owners of Inozyme Pharma, Inc. after tendering over 4.49 million shares in a BioMarin Pharmaceutical tender offer.

Beryl Capital Management and related entities report 0% beneficial ownership in Inozyme Pharma, Inc., signaling a complete divestment.

Rock Springs Capital and its affiliates have reported a complete divestment of their beneficial ownership in Inozyme Pharma, Inc., now holding 0% of common stock.

Adage Capital Management and its principals have filed an amendment indicating their beneficial ownership in Inozyme Pharma, Inc. will be 0% as of June 30, 2025, signaling a complete planned divestment.

Glazer Capital, LLC and its managing member Paul J. Glazer have disclosed a beneficial ownership of 6.59% of Inozyme Pharma, Inc.'s common stock, totaling 4,251,940 shares.

Affinity Healthcare Fund, LP and its investment manager, Affinity Asset Advisors, LLC, have filed an amended Schedule 13G disclosing a passive beneficial ownership of 2.89% in Inozyme Pharma, Inc.

Beryl Capital Management and its affiliates have disclosed a passive beneficial ownership of 9.8% of Inozyme Pharma, Inc.'s common stock, totaling 6,321,584 shares.